J&J ends Palomar deal
This article was originally published in The Gray Sheet
Executive Summary
Palomar says it will move forward with commercialization of its home-use, light-based technology for treatment of cellulite, skin aging and acne after Johnson & Johnson backed out of an agreement to market the product, citing economic conditions. The Burlington, Mass.-based firm received 510(k) clearance for the device for treatment of periorbital wrinkles in June (1"The Gray Sheet" June 15, 2009). Citing a multi-billion dollar market opportunity, Palomar CEO Joseph Caruso said the firm plans to launch the device for multiple applications in the second half of 2010. Near-term marketing efforts will focus on "certain specialty channels," Caruso said
You may also be interested in...
Palomar’s home-use laser for wrinkle removal
Palomar Medical Technologies gains 510(k) clearance June 5 for an over-the-counter, home-use laser for treatment of periorbital wrinkles - the first clearance of its kind, according to the company. The product will be marketed directly to consumers without a prescription by Johnson & Johnson under an existing agreement (1"The Gray Sheet" Sept. 13, 2004, p. 25). The device will enable laser wrinkle reduction "for a fraction of the cost" of similar treatments in the professional setting, according to Palomar
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.